Clinical, radiological and laboratorial characteristics in patients with COVID-19 treated by Jusvinza

Authors

Keywords:

COVID-19, Jusvinza, comorbidities, respiratory distress

Abstract

Introduction: The treatment with monoclonal antibodies in the infection by SARS-CoV-2 is controversial, some protocols recommend it for patients with an acute disease or in a critical status.  

Objective:  To characterize infected patients by COVID-19 admitted to the Intensive Care Unit under treatment with Jusvinza.  

Methods:  An observational, descriptive cross-sectional and prospective study was carried out with seven patients with acute disease by COVID-19, admitted to the Intensive Care Unit, in the Bolivarian Republic of Venezuela, from March to July, 2020. The cases were characterized according to the following variables: age, sex, comorbidities, associated symptoms; extension of the radiological lesions, clinical laboratory values; respiratory distress severity, time of ventilator support and hospital stay, complications and mortality. 

Results: The male sex and ages from 55 to 74 years old prevailed. Asthma was the most frequent comorbidity. The most frequent symptoms were cough, fever and asthenia. The diffuse bilateral infiltrate prevailed in the chest X-rays and neutrophilia with lymphopenia. According to the relation PO2/FIO2, moderate distress prevailed. Time of ventilator support for patients oscillated between 5 and 10 days, and hospital stay was more than 14 days. The most observed complication was pneumonia associated to ventilation and no deceased was registered.

Conclusions:  In patients with SARS-CoV-2 and acute diseases treated by Jusvinza, an average time of ventilator support less than seven days is observed and no deceased is registered. 

Downloads

Download data is not yet available.

Author Biographies

Yanet Damarys Acosta Perdomo, Facultad de Ciencias Medicas Mayabeque

Especialista de I grado en Anestesiologia y Reanimación , Diplomado en Medicina Natural y Tradicional. Asistente. Facultad de Ciencias Medicas Mayabeque.

Reinol Delfín García Moreira, Hospital Clínico Quirúrgico Hermanos Ameijeiras. La Habana.

Especialista de II grado en Cirugía Plástica y Caumatología. Profesora Auxiliar. La Habana.

Alexey Domínguez Mora, Hospital Enrique Cabrera. La Habana

Especialista de I Grado en Oftalmología . Asistente. Hospital Enrique Cabrera. La Habana

Isnelvis Del Carmen Felipe Fuentes, Filial de Ciencias Médicas de Contramaestre.Santiago de Cuba

Licenciada en Educación. Filial de Ciencias Médicas de Contramaestre.Santiago de Cuba

References

Organización Panamericana de la Salud[Internet]. Washington, D.C.: OPS; 2020[citado 21 Abr 2022]. Actualización Epidemiológica. Nuevo coronavirus (COVID-19), feb. 2020. Disponible en: https://covid19-evidence.paho.org/handle/20.500.12663/410

Serra Valdés MÁ. Infección respiratoria aguda por 2019-nCoV: una amenaza evidente. Rev Haban Cienc Méd [Internet]. 2020 [citado 21 Abr 2022]; 19(1):[aprox. 4 p.]. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/317

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [Internet]. 2020[citado 21 Abr 2022];395(10229):1033-4. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext

Lozada-Requena I, Núñez Ponce C. COVID-19: respuesta inmune y perspectivas terapéuticas. Rev Perú Med Exp Salud Publica[Internet]. 2020 [citado 21 Abr 2022]; 37(2): 312-9. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext pid=S1726-46342020000200312

Izquierdo-Cano L, Espinosa-Estrada E, Hernández-Padrón C, Ramón-Rodríguez L, Avila-Cabrera O, Hernández-Ramírez P, et al. Anticuerpo monoclonal humanizado itolizumab (anti-cd6) en síndromes linfoproliferativos cd 6+. Experiencia preliminar. Revista Cubana de Hematología, Inmunología y Hemoterapia [Internet]. 2014 [citado 21 Abr 2022];30(3): [aprox. 9 p.]. Disponible en: http://revhematologia.sld.cu/index.php/hih/article/view/148

Leiva-Suero LE, Morales JM, Villacís-Valencia SE, Escalona-Rabaza M, Quishpe-Jara GM, Hernández-Navarro EV, et al. Ébola, abordaje clínico integral. Rev Fac Med [Internet]. 2018 Sep [citado 21 Abr 2022];66(3):293-9. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-00112018000300293&lng=en.

Batista-Romagosa M, Gray-Lovio O, Falcón-Lincheta L, Pérez-Alonso T, Mantecón-Fernández B, Urquiza-Rodríguez A, et al. Eficacia y seguridad clínica del itolizumab en fase de inducción, en pacientes con psoriasis grave. Revista Cubana de Medicina Militar [Internet]. 2020 [citado 21 Abr 2022]; 49 (2): [aprox. 15 p.]. Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/477

Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M , et al . Tocilizumab in patients with severe COVID-19: a restrospective cohort study. Lancet Rehumatol[Internet].2020 [citado 21 Abr 2022];2(8):e474–e84. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314456/

Pérez Nieto OR, Zamarrón López EI, Guerrero Gutiérrez MA, Soriano Orozco R, Figueroa Uribe AF, López Fermín J, et al. Protocolo de manejo para la infección por COVID-19. Med Crit [Internet]. 2020[citado 24 Mar 2021];34(1):43-52. Disponible en: https://www.medigraphic.com/pdfs/medcri/ti-2020/ti201c.pdf

Venegas-Rodríguez R, Peña-Ruiz R, Santana-Sánchez R, Bequet-Romero M, Hernández-Cedeño M, Santiesteban-Licea B, et al. Péptido inmumodulador CIGB-258 para el tratamiento de pacientes graves y críticos con la COVID-19. Revista Cubana de Medicina Militar [Internet]. 2020 [citado 21 Abr 2022]; 49 (4): [aprox. 15 p.]. Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/926

Fei Z, Ting Y, Ronghui D, Du R, Fan, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet].2020[citado 21 Abr 2022]; 395 (10229): 1054–62. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270627/

Toniati P, Piva S, Catalina M, Garrafa E, Regola F, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev [Internet]. 2020 [citado 21 Abr 2022]; 19(7): 102568. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252115/

Serrano JL. Características y resultados de una serie de 59 pacientes con neumonía grave por COVID-19 ingresados en UCI. Med Intensiva[Internet]. 2020 [citado 21 Abr 2022]; 44(9): 580–3. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298456/

Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort. E Clinical Medicine [internet]. 2020 [citado 21 Abr 2022]; 24:100418 Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305505/

Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G et al. Tocilizumad Treatment for Cytoquine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes. Chest [Internet].2020 [citado 13 Abr 2020];158(4):1397-408.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831876/

Xu X, Han M, Li T, Sun W, Wang D, FuB et al. Effective treatment of severe COVID-19 patients with Tocilizumab. Proc Natl Acad Sci U S A [Internet].2020 [citado 21 Abr 2022]; 117(20): 10970–5.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245089/

Leonard -Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, Collange O, et al. Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D Dimer Levels. Radiology [Internet]. 2020 [citado 21 Abr 2022];296(3):E189-E91. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233397/

Bompard F, Monnier H, Saab I, Tordjman M, Abdoul H, Fournier l, et al Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J [Internet]. 2020 [citado 21 Abr 2022]; 56(1):2001608. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236820/

Venegas IribarrenI S, Valdés Ochagavia R, Palacios Matra S, Soto Fajardo S, Schiappacasse Faundes G, et al. Hallazgos y complicaciones extrapulmonares en pacientes con neumopatía Covid-19: Experiencia local y revisión de la literatura. Rev Chil Radiol [Internet]. 2021 [citado 21 Abr 2022];27(2):66-75. Disponible en: http://cl.submission.scielo.org/index.php/rchradiol/article/view/7727

Downloads

Published

2022-06-07

How to Cite

1.
Acosta Perdomo YD, García Moreira RD, Domínguez Mora A, Felipe Fuentes IDC. Clinical, radiological and laboratorial characteristics in patients with COVID-19 treated by Jusvinza. Medimay [Internet]. 2022 Jun. 7 [cited 2024 Dec. 22];29(2):218-2. Available from: https://medimay.sld.cu/index.php/rcmh/article/view/1722

Issue

Vol. 29 No. 2 (2022)

Section

ORIGINAL ARTICLES

License

Medimay protects copyright from the very first moment the submission is made, but upon publication it assumes a Creative Commons 4.0 (cc-by-nc) license, which allows the use of the work to share (copy and redistribute the material in any medium or format) and adapt (remix, transform and build from the material) as long as exclusive mention is made of the publication in the journal as a primary source, prohibiting its commercialization. The author always retains his/her right.

Most read articles by the same author(s)